Relapsed acute lymphoblastic leukemia (ALL) has remained challenging to treat in children,
with survival rates lagging well behind those observed at initial diagnosis. Although there …

Background Missing data are common in medical research, which can lead to a loss in
statistical power and potentially biased results if not handled appropriately. Multiple …

Importance Standard chemotherapy for first relapse of B-cell acute lymphoblastic leukemia
(B-ALL) in children, adolescents, and young adults is associated with high rates of severe …

Importance Blinatumomab is a CD3/CD19-directed bispecific T-cell engager molecule with
efficacy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) …

Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on
B-cell lymphoblasts. We evaluated the safety, pharmacokinetics, recommended dosage, and …

Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. It
has an overall survival of approximately 80%, with certain subsets experiencing greater than …

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy.
Advancements in technology that enhance our understanding of the biology of the disease …

Minimal residual disease (MRD) is highly prognostic in pediatric B-precursor acute
lymphoblastic leukemia (B-ALL). In Children's Oncology Group high-risk B-ALL study …

Importance Anthracyclines are part of many effective pediatric cancer treatment protocols.
Most pediatric oncology treatment groups assume that the hematologic toxicity of …

With steadily improved cure rates for children with newly diagnosed acute lymphoblastic
leukaemia (ALL), treating relapsed ALL has become increasingly challenging largely due to …